Income Statement
ENTRADA THERAPEUTICS, INC.
TRDA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
25.42 | 210.78 | 129.01 | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
25.42 | 210.78 | 129.01 | - | - |
|
Operating Expenses
|
183.32 | 163.77 | 132.18 | 97.25 | 51.13 |
|
Research & Development
|
142.27 | 125.31 | 99.88 | 66.61 | 35.93 |
|
Selling, General & Administrative
|
41.05 | 38.47 | 32.29 | 30.64 | 15.20 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-157.90 | 47.01 | -3.16 | -97.25 | -51.13 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
15.07 | 19.47 | 15.22 | 2.63 | -0.03 |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
0.92 | 0.86 | 18.74 | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-143.75 | 65.63 | -6.69 | -94.62 | -51.16 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-157.90 | 47.01 | -3.16 | -97.25 | -51.13 |
|
Earnings Per Share (Basic)
|
-3.47 | 1.76 | -0.20 | -3.02 | -8.16 |
|
Diluted EPS
|
-3.47 | 1.68 | -0.20 | -3.02 | -8.16 |
|
Weighted Average Shares
|
41.37 | 37.31 | 33.05 | 31.29 | 6.27 |
|
Diluted Weighted Avg Shares
|
41.37 | 39.00 | 33.05 | 31.29 | 6.27 |
|
Comprehensive Income
|
-143.06 | 65.39 | -4.43 | -96.67 | - |